2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: L7

Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Abstract Number: 2329

Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
Abstract Number: 987

Improving Access To Subspecialty Care For Underserved Communities: A Rheumatology Patient Navigator Pilot Intervention
Abstract Number: 845

Improving Pneumococcal Vaccination Rate In The Pediatric Rheumatology Clinic
Abstract Number: 1789

In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial
Abstract Number: 2379

In Rheumatoid Arthritis Patients With Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation Of Etanercept Is Superior Both Clinically and Radiographically To Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
Abstract Number: 2394

In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies
Abstract Number: 1619

In Vitro Assessments Of Mesenchymal Stem Cells From Lupus Patients To Predict Suppressive Function In Vivo
Abstract Number: 2554

In Vitro Fertilization In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Series Of 82 Cycles
Abstract Number: 2722

In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Abstract Number: 1828

In Vivo Cartilage-Specific Deletion Of Ephrin-B2 In Mice Results In Developmental Locomotory Defects Associated With Hip Bone Abnormality
Abstract Number: 2737

In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Abstract Number: 570

In Vivo Therapeutic Success Of Microrna-155 (miR-155) Antagomir In a Mouse Model Of Lupus Pulmonary Hemorrhage
Abstract Number: 2537

Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Abstract Number: 1281

Inadequate Glucocorticoid Secretion in Experimental Arthritis in Rats Is Closely Linked to Impaired Mitochondria and Reduced Lipid Breakdown in the Adrenal Cortex

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].